RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (rtPA) INJECTION 52.5MG – EMERGENCY THROMBOLYTIC "CLOT-BUSTER" THERAPY

Recombinant Tissue Plasminogen Activator (commonly known as Alteplase) is a potent thrombolytic agent produced by recombinant DNA technology. It works through a high-precision biochemical mechanism: it binds to fibrin in a thrombus (blood clot) and selectively converts entrapped plasminogen into Plasmin. This plasmin then digests the fibrin network, effectively dissolving the clot and restoring critical blood flow to oxygen-starved tissues.

In Nigeria, rtPA (available as Actilyse or brand equivalents) is a life-saving critical care medication. It is primarily managed through tertiary health institutions and specialized cardiovascular centers in collaboration with pharmacies like Sanlive Pharmacy, ensuring that these high-value, temperature-sensitive vials are stored in strict cold-chain environments ($2$°C to $8$°C) to maintain the molecular integrity of the protein.

Important: This is a high-alert, hospital-only emergency medication. The "Golden Hour" Rule: For ischemic stroke, this medication is most effective when administered within 3 to 4.5 hours of the onset of symptoms; beyond this window, the risk of brain bleeding often outweighs the benefits. The "Bleeding" Warning: Because it dissolves clots throughout the body, the most serious risk is internal bleeding (hemorrhage). The "Screening" Note: A CT scan or MRI must be performed before administration to rule out a brain bleed, as giving rtPA during a hemorrhagic stroke is fatal.

Key Uses & Benefits

rtPA Injection 52.5mg is primarily used for:

• Acute Ischemic Stroke: Dissolving clots in the brain to prevent permanent paralysis or disability

• Acute Myocardial Infarction (Heart Attack): Restoring blood flow to the heart muscle when given within 6–12 hours

• Acute Massive Pulmonary Embolism: Dissolving life-threatening clots in the lungs to restore respiratory and heart function

• Clearing Occluded Catheters: In lower doses, to open central venous access devices blocked by fibrin

• Rapidly Restoring Tissue Perfusion, which can significantly improve long-term survival rates

• Reducing the long-term Neurological Deficit in stroke survivors

• Providing a "Non-Invasive" alternative to surgical clot removal (thrombectomy) in some cases

Who Should Receive rtPA?

This medication is intended for:

• Patients with a confirmed diagnosis of acute ischemic stroke, heart attack, or massive pulmonary embolism

• Individuals within the specific "time-to-treatment" clinical window

• Patients who meet strict inclusion criteria after a comprehensive medical screening

Not recommended for: Use outside of a monitored intensive care or emergency setting. It is strictly contraindicated for anyone with active internal bleeding, a history of recent intracranial hemorrhage, recent major surgery (within 14 days), or severe uncontrolled high blood pressure (e.g., Systolic $>185$ mmHg). Use with extreme caution in patients over 80 years of age or those on "Blood Thinners" (like Warfarin or Heparin). Consult the attending consultant if the patient has a history of severe liver disease or a known bleeding disorder. During pregnancy, it is only used in life-threatening situations where no other option exists.

Suggested Clinical Administration

• Strictly Intravenous (IV) Use: Must be reconstituted with Sterile Water for Injection to a concentration of $1$ mg/mL.

• The "Bolus" Rule: Usually, $10$% of the total dose is given as an initial IV bolus over 1 minute, followed by the remaining $90$% as a continuous infusion over 60 minutes.

• The "Weight-Based" Dose: The total dose is calculated based on the patient's actual body weight (usually $0.9$ mg/kg, not to exceed $90$ mg total).

• The "Monitoring" Tip: Blood pressure and neurological status must be monitored every 15 minutes during the infusion and for several hours afterward.

• The "No Injections" Rule: Avoid starting new IV lines or giving IM injections for 24 hours after treatment to prevent bleeding at puncture sites.

• If signs of a brain bleed occur (sudden headache, nausea, or decreased consciousness), the infusion must be stopped immediately.

Common Side Effects

rtPA is a high-risk medication; while it saves lives, it can cause:

• Internal Bleeding: Ranging from mild bruising to life-threatening brain or stomach hemorrhages

• Bleeding from the gums, nose, or previous injection sites

• Low blood pressure (Hypotension) and rapid heart rate

• Nausea and vomiting

• Rare but serious: Angioedema (swelling of the tongue and throat), especially in patients taking ACE inhibitors

• Rare: Fever or chills (infusion-related reactions)

Seek immediate surgical intervention if the patient shows signs of intracranial pressure, severe abdominal pain (internal bleeding), or anaphylaxis.

Manufacturer

Boehringer Ingelheim (Germany) or Genentech (USA) – The global leaders in biotechnological thrombolytics, ensuring that every 52.5mg vial is manufactured under clean-room conditions with validated enzymatic activity.

Why Source rtPA via Sanlive Pharmacy?

• 100% authentic biological stock—guaranteed original Actilyse/Alteplase with verified cold-chain logs.

• Guaranteed Continuous Cold-Chain Management from arrival in Nigeria to delivery at the hospital.

• Professional coordination with hospital pharmacies and emergency departments for rapid procurement.

• Support for medical teams in verifying batch numbers and expiration dates for high-value emergency stock.

Frequently Asked Questions (FAQs)

Why 52.5mg? Is that the only dose?

Standard vials often come in 50mg or 20mg sizes; a 52.5mg presentation (including overfill or specific brand sizing) is used to ensure the patient receives the exact calculated dose for their weight without running out of reconstituted solution mid-infusion.

Can this be used for "Stroke" at home?

Absolutely not. This medication can cause fatal bleeding if used incorrectly. It must only be administered in a hospital with a CT scanner and an ICU team ready to manage complications.

Is it different from "Heparin"?

Yes. Heparin prevents new clots from forming. rtPA (Alteplase) dissolves the clot that has already formed and is currently blocking blood flow.

Where can I purchase rtPA Injection in Nigeria?

Due to the emergency nature and cold-chain requirements, you can coordinate the procurement of verified rtPA through Sanlive Pharmacy & Stores for delivery to your designated tertiary medical facility.